Literature DB >> 33725867

NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient: A case report.

Yuan-Yuan Jin1, Wen-Zhuo Yang2, Zheng-Yang Sun1, Zhong-Bo Wang1, Jian Chen3, Chun-Tao Wu4, Zhao-Yong Yang1.   

Abstract

RATIONALE: Advanced signet ring cell (SRC) carcinoma has a worse prognosis. Therefore, early diagnosis and prevention is particularly important; SRC tumors have lower R0 resection rate and are thought to be less chemosensitive than non-SRCC. Consequently, a novel postoperative adjuvant treatment is urgently needed to improve clinical outcomes. PATIENT CONCERNS: A 41-year-old female with advanced gastric SRC carcinoma was treated with radical gastrectomy and oxaliplatin-based regimen for 6 cycles after surgery. She was suspected of recurrence with the high level of carbohydrate antigen (CA) 72-4. DIAGNOSES: The gastroscopy revealed SRC carcinoma of gastric antrum and poorly differentiated adenocarcinoma in some areas. The diagnosis of postoperative pathology report was gastric cancer with stage III C (T4a, N3a, M0).
INTERVENTIONS: The level of CA72-4 rapidly increased during the 2 follow-up after the completion of conventional treatment, ex vivo-cultured allogeneic natural killer (NK) cell infusion was offered to prevent recurrence. OUTCOMES: Intravenous injections of NK cells combination with surgical treatment and chemotherapy showed therapeutic effects in this patient with possible relapse. The patient remained disease-free 46 months after the infusion of NK cells until the latest follow-up. LESSONS: CA72-4 appeared to be the most sensitive and specific marker in the gastric cancer patient, and the high level of CA72-4 may indicate the risk of recurrence. This case report provide rationale for NK cell infusion following the rapid increase of CA72-4 to prevent recurrence.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33725867      PMCID: PMC7969222          DOI: 10.1097/MD.0000000000024979

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  39 in total

1.  Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Authors:  Simon Pernot; Magali Terme; Nina Radosevic-Robin; Florence Castan; Cécile Badoual; Elie Marcheteau; Fréderique Penault-Llorca; Olivier Bouche; Jaafar Bennouna; Eric Francois; Francois Ghiringhelli; Christelle De La Fouchardiere; Emmanuelle Samalin; Jean Baptiste Bachet; Christophe Borg; Valérie Boige; Thibault Voron; Trevor Stanbury; Eric Tartour; Sophie Gourgou; David Malka; Julien Taieb
Journal:  Gastric Cancer       Date:  2019-07-02       Impact factor: 7.370

2.  Gastric cancer.

Authors:  Tetsuji Fujita
Journal:  Lancet       Date:  2009-11-07       Impact factor: 79.321

Review 3.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

Authors:  Xavier Paoletti; Koji Oba; Tomasz Burzykowski; Stefan Michiels; Yasuo Ohashi; Jean-Pierre Pignon; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Eric Van Cutsem; Marc Buyse
Journal:  JAMA       Date:  2010-05-05       Impact factor: 56.272

4.  Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development.

Authors:  K Moitra; H Lou; M Dean
Journal:  Clin Pharmacol Ther       Date:  2011-03-02       Impact factor: 6.875

Review 5.  Metastatic gastric cancer (MGC) patients: Can we improve survival by metastasectomy? A systematic review and meta-analysis.

Authors:  Rahul Gadde; Leonardo Tamariz; Mena Hanna; Eli Avisar; Alan Livingstone; Dido Franceschi; Danny Yakoub
Journal:  J Surg Oncol       Date:  2015-06-12       Impact factor: 3.454

6.  Natural killer cells and metastases from pharyngeal carcinoma.

Authors:  S P Schantz; H E Savage; T Racz; D L Taylor; P G Sacks
Journal:  Am J Surg       Date:  1989-10       Impact factor: 2.565

7.  Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.

Authors:  Yan Li; Ying Yang; Ming Lu; Lin Shen
Journal:  Hepatogastroenterology       Date:  2011 Nov-Dec

8.  Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats.

Authors:  G G Page; W P Blakely; S Ben-Eliyahu
Journal:  Pain       Date:  2001-02-01       Impact factor: 6.961

9.  The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.

Authors:  I Kodama; K Koufuji; S Kawabata; S Tetsu; Y Tsuji; J Takeda; T Kakegawa
Journal:  Int Surg       Date:  1995 Jan-Mar

Review 10.  Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications.

Authors:  Anushruti Sarvaria; Dunia Jawdat; J Alejandro Madrigal; Aurore Saudemont
Journal:  Front Immunol       Date:  2017-03-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.